ERBB2 and breast cancer: Several other clinical trials are currently ongoing, including DESTINY-breast05 and DESTINY-breast09 that, respectively, evaluate Enhertu in patients with residual disease after neo-adjuvant therapy in HER2 + BC or versus current first-line standard of care regimen in HER2 + BC, again illustrating its success.